4DMT Announces Promising Financial Results and Key Clinical Developments
March 1, 2025 - 00:01
4DMT has reported encouraging interim data from its ongoing clinical trials, showcasing significant advancements in its treatment for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The results from the PRISM Phase 1/2 trial for 4D-150 indicate robust and durable clinical activity across a diverse patient population, with a favorable tolerability profile observed over a 52-week period and beyond.
In addition to the AMD findings, the company also revealed positive interim results from the SPECTRA clinical trial, specifically from Part 1, which focuses on DME. These 32-week data results are pivotal as they demonstrate the potential effectiveness of 4D-150 in treating this condition.
Moreover, 4DMT has achieved alignment with the FDA regarding its development strategy, indicating that a single Phase 3 trial could be sufficient for a Biologics License Application (BLA) submission for 4D-150 in DME, especially when combined with data from the 4FRONT study. This strategic direction marks a significant milestone for the company as it seeks to advance its therapeutic offerings in the ophthalmology space.
MORE NEWS
March 19, 2026 - 04:45
Climate Finance Has Failed Africa Twice Over. Here’s How To Fix It.The global system designed to fund climate action is failing Africa profoundly and on two critical fronts. Not only is the continent receiving a minuscule fraction of the necessary financing to...
March 18, 2026 - 21:44
Fed meeting live updates: Federal Reserve holds rates steady, forecasts 1 rate cut in 2026In a widely anticipated move, the Federal Reserve concluded its June policy meeting by holding its benchmark interest rate steady at a 23-year high. The decision underscores the central bank`s...
March 18, 2026 - 00:00
New Rules Reshape the Home Equity Line of Credit LandscapeThe familiar flexibility of the Home Equity Line of Credit (HELOC) is undergoing a significant shift. Driven largely by nonbank lenders entering the market, new requirements are emerging that could...
March 17, 2026 - 04:47
Close Brothers plunges as short seller claims it understated car finance risksShares in Close Brothers Group suffered a dramatic fall, dropping as much as 14% in a single trading session. The sharp decline was triggered by a report from short-selling firm Viceroy Research,...